ClinicalTrials.gg
CompletedNCT02457559Updated Mar 24, 2022Results posted

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1 interventional study of Tirabrutinib in Relapsed/Refractory B-cell Malignancies, sponsored by Gilead Sciences. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-24.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to determine the long-term safety and tolerability of tirabrutinib in adults with relapsed/refractory B-cell malignancy who have tolerated and achieved stable disease or improved with tirabrutinib treatment while enrolled in a prior (parent study) tirabrutinib study (NCT01659255). The dosing regimen will be based on the prior dosing regimen from the parent study.

02

Conditions studied

  • Relapsed/Refractory B-cell Malignancies

Browse trials for

03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently enrolled in a prior tirabrutinib study
  • Did not discontinue treatment with tirabrutinib for any reason other than to enroll in this study
  • (ECOG) performance status of 0, 1, or 2 at enrollment in this study
  • Any Grade 3 or 4 non-hematologic toxicity that the investigator considers related to previous tirabrutinib use must have resolved, reverted to Grade 1, or reverted to the baseline of the prior study prior to Day 1 of this study
  • Negative serum and urine pregnancy test is required for female individuals (unless surgically sterile or greater than 2 years post menopausal)
  • Male and female individuals of who engage in heterosexual intercourse must agree to use protocol specified method(s) of as described in the protocol
  • Lactating females must agree to discontinue nursing before the study drug is administered
  • Ability and agreement to attend protocol-specified visits at the study site
  • Able to comprehend and willing to sign the form

Key Exclusion Criteria:

  • Known to tirabrutinib, its metabolites, or formulation

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Tirabrutinib 40 mg once daily (CLL)

    Participants with relapsed/refractory chronic lymphocytic leukemia (CLL) received tirabrutinib 40 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 80 mg once daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 160 mg once daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 320 mg once daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 400 mg once daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 500 mg once daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 600 mg once daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 300 mg twice daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 160 mg once daily (NHL)

    Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 320 mg once daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 480 mg once daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 600 mg once daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.

    Drug: Tirabrutinib

Interventions

  • Tablets or capsules administered orally

    Also known as: ONO/GS-4059

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)

    Treatment-emergent AEs were defined as one or both of the following: * Any AEs with an onset date on or after the study drug start date of parent study and no later than 30 days after permanent discontinuation of study drug in this rollover study; * Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study

  2. Percentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities

    Treatment-emergent marked laboratory abnormalities were defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of study drug plus 30. If the relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the timeframe specified above will be considered treatment-emergent marked abnormalities. Laboratory assessments included tests for Chemistry, Hematology, Coagulation and Urinalysis.

    Time frame: First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined per Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for CLL and Cheson, 2007 criteria for NHL as percentage of participants who achieve partial response (PR) or complete response (CR) in either parent or roll-over study. CLL:CR: lymphocytes (Ly) \<4\*10\^9/L, no lymphadenopathy,normal spleen and liver size,absence of disease, absolute neutrophil count (ANC) \>1.5\*10\^9/L,platelets ≥100\*10\^9/L, hemoglobin (Hb) \>110 g/L,bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy,size of liver and spleen, bone marrow infiltrates;and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters (LD) of all index lesions,no new lesions;no increase in size of liver or spleen;persistence of bone marrow involvement in participant who meets other criteria for CR.

    Time frame: Up to 39 months in parent study and up to 60 months in rollover study

  2. Duration of Response (DOR)

    DOR was defined per IWCLL 2008 criteria for CLL and Cheson, 2007 criteria for NHL as the interval from first documentation of CR or PR to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause in subjects who achieve a response. CLL:CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of the LD of all index lesions, no new lesions; no increase in size of liver or spleen; persistence of bone marrow involvement in participant who meets other criteria for CR.

    Time frame: From first documentation of CR or PR to the first documentation of disease progression or death from any cause up to 39 months in parent study and up to 60 months in the rollover study

  3. Progression-free Survival (PFS)

    PFS was defined per IWCLL 2008 criteria for CLL and Cheson 2007 criteria for NHL as the interval from date of the first dose of tirabrutinib on the parent study to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause. Progressive disease (PD) in CLL: Lymphadenopathy, or appearance of any new lesion/organomegaly, \> 50% increase in the size of the liver and/or spleen, Decrease in platelet count or hemoglobin attributable to CLL per IWCLL, Transformation to a more aggressive histology (eg, Richter syndrome). PD in NHL: Cheson, 2007: Appearance of new lesion or increase by \>50% of previously involved sites from nadir, Transformation to a more aggressive NHL histology.

    Time frame: From first dose of tirabrutinib in the parent study (NCT01659255) to the first documentation of disease progression or death from any cause up to 99 months

  4. Overall Survival (OS)

    OS is defined as the interval from date of the first dose of tirabrutinib on the parent study until death from any cause.

    Time frame: From first dose of tirabrutinib in the parent study (NCT01659255) until death from any cause up to 99 months

07

Results

Posted Mar 24, 2022

Participant flow

Participants were enrolled at study sites in the United Kingdom and France. The first participant was screened on 10 September 2015. The last study visit occurred on 30 December 2020.

Participant flow — Overall Study
MilestoneTirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Started23721221342
Completed00020001000
Not completed23701220342
Withdrew: Progressive disease12300210111
Withdrew: Investigator's discretion00201010101
Withdrew: Adverse event01200000000
Withdrew: Reason not specified10000000020
Withdrew: Death00000000110

Outcome measures

PrimaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)

Treatment-emergent AEs were defined as one or both of the following: * Any AEs with an onset date on or after the study drug start date of parent study and no later than 30 days after permanent discontinuation of study drug in this rollover study; * Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)
percentage of participantsTirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
PrimaryPercentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities

Treatment-emergent marked laboratory abnormalities were defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of study drug plus 30. If the relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the timeframe specified above will be considered treatment-emergent marked abnormalities. Laboratory assessments included tests for Chemistry, Hematology, Coagulation and Urinalysis.

Time frame:
First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities
percentage of participantsTirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Percentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities100.0100.066.771.4100.0100.0100.050.0033.350.050.0
SecondaryOverall Response Rate (ORR)

ORR was defined per Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for CLL and Cheson, 2007 criteria for NHL as percentage of participants who achieve partial response (PR) or complete response (CR) in either parent or roll-over study. CLL:CR: lymphocytes (Ly) \<4\*10\^9/L, no lymphadenopathy,normal spleen and liver size,absence of disease, absolute neutrophil count (ANC) \>1.5\*10\^9/L,platelets ≥100\*10\^9/L, hemoglobin (Hb) \>110 g/L,bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy,size of liver and spleen, bone marrow infiltrates;and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters (LD) of all index lesions,no new lesions;no increase in size of liver or spleen;persistence of bone marrow involvement in participant who meets other criteria for CR.

Time frame:
Up to 39 months in parent study and up to 60 months in rollover study
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsTirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Overall Response Rate (ORR)100.0 (15.8 to 100)100.0 (29.2 to 100)100.0 (59 to 100)100.0 (15.8 to 100)100.0 (2.5 to 100)100.0 (15.8 to 100)100.0 (15.8 to 100)100.0 (2.5 to 100)100.0 (29.2 to 100)100.0 (39.8 to 100)50.0 (1.3 to 98.7)
SecondaryDuration of Response (DOR)

DOR was defined per IWCLL 2008 criteria for CLL and Cheson, 2007 criteria for NHL as the interval from first documentation of CR or PR to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause in subjects who achieve a response. CLL:CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of the LD of all index lesions, no new lesions; no increase in size of liver or spleen; persistence of bone marrow involvement in participant who meets other criteria for CR.

Time frame:
From first documentation of CR or PR to the first documentation of disease progression or death from any cause up to 39 months in parent study and up to 60 months in the rollover study
Reported as:
Median · months
Duration of Response (DOR)
monthsTirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Duration of Response (DOR)NA (61.7 to NA)27.0 (26.3 to 42.3)57.7 (39.8 to NA)NA (76.6 to NA)NA (NA to NA)33.6 (25.7 to 41.4)NA (33.6 to NA)NA (NA to NA)63.2 (23.9 to 63.2)71.4 (53.6 to NA)37.0 (37.0 to 37.0)
SecondaryProgression-free Survival (PFS)

PFS was defined per IWCLL 2008 criteria for CLL and Cheson 2007 criteria for NHL as the interval from date of the first dose of tirabrutinib on the parent study to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause. Progressive disease (PD) in CLL: Lymphadenopathy, or appearance of any new lesion/organomegaly, \> 50% increase in the size of the liver and/or spleen, Decrease in platelet count or hemoglobin attributable to CLL per IWCLL, Transformation to a more aggressive histology (eg, Richter syndrome). PD in NHL: Cheson, 2007: Appearance of new lesion or increase by \>50% of previously involved sites from nadir, Transformation to a more aggressive NHL histology.

Time frame:
From first dose of tirabrutinib in the parent study (NCT01659255) to the first documentation of disease progression or death from any cause up to 99 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsTirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Progression-free Survival (PFS)NA (63.5 to NA)44.0 (28.1 to 44.1)59.5 (41.6 to NA)NA (78.5 to NA)NA (NA to NA)35.4 (27.6 to 43.3)NA (39.1 to NA)NA (NA to NA)65.0 (25.8 to NA)73.2 (57.3 to NA)NA (38.9 to NA)
SecondaryOverall Survival (OS)

OS is defined as the interval from date of the first dose of tirabrutinib on the parent study until death from any cause.

Time frame:
From first dose of tirabrutinib in the parent study (NCT01659255) until death from any cause up to 99 months
Reported as:
Median · months
Overall Survival (OS)
monthsTirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)
Overall Survival (OS)NA (NA to NA)NA (44.8 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (40.8 to NA)NA (NA to NA)NA (65.0 to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over All-Cause Mortality: Enrollment up to 39 months in parent study and up to 61months in the rollover study Adverse Events (AE): First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirabrutinib 40 mg QD (CLL)—0/1 (0%)1/1 (100%)
Tirabrutinib 80 mg QD (CLL)0/2 (0%)2/2 (100%)2/2 (100%)
Tirabrutinib 160 mg QD (CLL)1/3 (33.3%)3/3 (100%)3/3 (100%)
Tirabrutinib 320 mg QD (CLL)1/7 (14.3%)5/7 (71.4%)7/7 (100%)
Tirabrutinib 400 mg QD (CLL)0/2 (0%)1/2 (50%)2/2 (100%)
Tirabrutinib 500 mg QD (CLL)0/1 (0%)0/1 (0%)1/1 (100%)
Tirabrutinib 600 mg QD (CLL)0/2 (0%)1/1 (100%)1/1 (100%)
Tirabrutinib 300 mg BID (CLL)1/2 (50%)1/2 (50%)2/2 (100%)
Tirabrutinib 160 mg QD (NHL)0/1 (0%)0/1 (0%)1/1 (100%)
Tirabrutinib 320 mg QD (NHL)1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Tirabrutinib 480 mg QD (NHL)1/4 (25%)4/4 (100%)4/4 (100%)
Tirabrutinib 600 mg QD (NHL)0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventTirabrutinib 40 mg QD (CLL)Tirabrutinib 80 mg QD (CLL)Tirabrutinib 160 mg QD (CLL)Tirabrutinib 320 mg QD (CLL)Tirabrutinib 400 mg QD (CLL)Tirabrutinib 500 mg QD (CLL)Tirabrutinib 600 mg QD (CLL)Tirabrutinib 300 mg BID (CLL)Tirabrutinib 160 mg QD (NHL)Tirabrutinib 320 mg QD (NHL)Tirabrutinib 480 mg QD (NHL)Tirabrutinib 600 mg QD (NHL)
H3n2 influenzaInfections and infestations0/10/20/30/70/20/11/10/20/10/30/40/2
SepsisInfections and infestations0/10/20/31/70/20/11/10/20/10/30/40/2
Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10/20/30/70/20/11/10/20/10/30/40/2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/10/20/30/70/20/11/10/20/10/30/40/2
NeutropeniaBlood and lymphatic system disorders0/10/20/31/71/20/10/10/20/10/30/40/2
Anal haemorrhageGastrointestinal disorders0/10/20/30/70/20/10/11/20/10/30/40/2
PyrexiaGeneral disorders0/10/21/32/71/20/10/10/20/10/31/40/2
InfluenzaInfections and infestations0/10/20/30/70/20/10/10/20/10/30/41/2
Lower respiratory tract infectionInfections and infestations0/11/21/32/70/20/10/11/20/10/32/40/2
Ophthalmic herpes zosterInfections and infestations0/10/20/30/70/20/10/10/20/10/30/41/2
Most frequent other events
Showing 10 of 361
Most frequent other events
EventTirabrutinib 40 mg QD (CLL)Tirabrutinib 80 mg QD (CLL)Tirabrutinib 160 mg QD (CLL)Tirabrutinib 320 mg QD (CLL)Tirabrutinib 400 mg QD (CLL)Tirabrutinib 500 mg QD (CLL)Tirabrutinib 600 mg QD (CLL)Tirabrutinib 300 mg BID (CLL)Tirabrutinib 160 mg QD (NHL)Tirabrutinib 320 mg QD (NHL)Tirabrutinib 480 mg QD (NHL)Tirabrutinib 600 mg QD (NHL)
AnaemiaBlood and lymphatic system disorders0/10/21/32/71/20/10/11/20/11/32/42/2
LymphopeniaBlood and lymphatic system disorders0/10/21/31/70/20/10/10/21/11/31/40/2
NeutropeniaBlood and lymphatic system disorders0/11/23/31/72/20/11/10/21/11/30/41/2
ThrombocytopeniaBlood and lymphatic system disorders0/10/22/32/70/20/10/11/21/10/30/41/2
Cerumen impactionEar and labyrinth disorders0/10/20/30/70/20/11/10/20/10/30/40/2
Ear painEar and labyrinth disorders0/10/21/31/70/20/11/10/20/11/30/40/2
Ear pruritusEar and labyrinth disorders0/10/20/30/70/20/11/10/20/10/30/40/2
VertigoEar and labyrinth disorders0/10/20/30/70/20/11/10/20/10/30/40/2
Ocular hyperaemiaEye disorders1/10/21/30/70/20/10/10/20/10/30/40/2
Abdominal pain upperGastrointestinal disorders1/11/20/31/70/20/10/10/21/10/32/40/2

Baseline characteristics

Full Analysis Set included all enrolled participants who took at least 1 dose of study drug in the study. The data for this study are summarized by integrating the parent (NCT01659255) study data and rollover study data.

Age, Categorical
Age, Categorical(Participants)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Total
<=18 years000000000000
Between 18 and 65 years2032000111111
>=65 years0340122023118
Sex: Female, Male
Sex: Female, Male(Participants)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Total
Female111000100206
Male1262121132223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Total
Race — White2352022124225
Race — Other002010001004
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Total
Ethnicity — Hispanic or Latino000000000000
Ethnicity — Not Hispanic or Latino2372122134229
Region of Enrollment
Region of Enrollment(participants)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Total
United Kingdom2232021124120
France014010101019
08

Study locations

6 sites
  • CHRU de Lille
    Lille, Nord 59037, France
  • Hopital Saint Eloi
    Montpellier, 34295, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69310, France
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Derriford Hospital
    Plymouth, PL68DH, United Kingdom
09

References and documents

Publications

  • Yu H, Truong H, Mitchell SA, Liclican A, Gosink JJ, Li W, Lin J, Feng JY, Jurgensmeier JM, Billin A, Xu R, Patterson S, Pagratis N. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement. SLAS Discov. 2018 Oct;23(9):919-929. doi: 10.1177/2472555218786165. Epub 2018 Jul 16. PubMed 30011241 ↗
  • Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, Salles G, Dyer MJS. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia. 2020 May;34(5):1458-1461. doi: 10.1038/s41375-019-0658-7. Epub 2019 Dec 11. No abstract available. PubMed 31827243 ↗
  • Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017 May 18;129(20):2808-2810. doi: 10.1182/blood-2017-02-765115. Epub 2017 Apr 4. No abstract available. PubMed 28377400 ↗
  • Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. PubMed 26542378 ↗
  • Walter HS, Salles GA, Dyer MJ. New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674. No abstract available. PubMed 27248633 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Dec 2020, 63 months.

Results were first posted in Mar 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
May 29, 2015
StartActual
Sep 10, 2015
Primary completionActual
Dec 30, 2020
CompletionActual
Dec 30, 2020
Results first posted
Mar 24, 2022
Last update
Mar 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02457559
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 29, 2015
Start date
Sep 10, 2015
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020
Results posted
Mar 24, 2022
Last update
Mar 24, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion